|
WO2021033145A1
|
|
Novel injectable formulations of artesunate
|
|
WO2020240514A1
|
|
Stable formulations of indocyanine green
|
|
US2021008081A1
|
|
Oral liquid formulations of abiraterone
|
|
WO2019123406A1
|
|
Novel formulations of vasopressin
|
|
EP3672964A1
|
|
Novel triple combination formulations for antiemetic therapy
|
|
WO2018042363A1
|
|
Pharmaceutical formulations of regadenoson
|
|
WO2018029624A1
|
|
Subcutaneous formulations of palonosetron
|
|
US2019151234A1
|
|
Stable liquid pharmaceutical formulations of bendamustine
|
|
WO2017115284A1
|
|
Novel co-crystal forms of agomelatine
|
|
WO2017085696A1
|
|
Parenteral formulations of melphalan
|
|
US2019060217A1
|
|
Novel levothyroxine formulations for oral use
|
|
GB201807634D0
|
|
Novel levothyroxine formulations for oral use
|
|
WO2017046694A1
|
|
Process for preparing a pharmaceutical formulation of gadoterate meglumine
|
|
WO2017037645A1
|
|
Stable pharmaceutical formulations of teriflunomide
|
|
WO2017037647A1
|
|
Stable pharmaceutical compositions of abiraterone
|
|
WO2017021880A1
|
|
Liquid formulations of fosaprepitant
|
|
WO2017013591A1
|
|
Stabilized liquid formulation of levothyroxine
|
|
US2018193255A1
|
|
Stable liquid formulations of melphalan
|
|
GB201720793D0
|
|
Stable liquid formulations of pemetrexed
|
|
WO2016189504A1
|
|
Non-lyophilized compositions of aripiprazole and methods of preparation thereof
|
